TRACT Therapeutics, Inc. has developed a novel approach for restoring immune balance in patients receiving a solid organ transplant or in patients suffering from an autoimmune disease. This therapeutic approach may potentially reduce the chance of organ rejection following a transplant or transfer a patient suffering from an autoimmune disease into a state of remission.
The proprietary technology is based on a platform which can be utilized to treat solid organ transplant patients, as well as a number of autoimmune disorders such as Crohn’s Disease. For organ transplant, it shows great promise in preventing rejection of a donated organ, thereby, reducing the need for a second transplant. Over the next few years, TRACT’s TregCel™ personalized therapy could transform the medical approach in transplant medicine by dramatically reducing or eliminating the lifelong use of toxic anti-rejection drugs.
Company Details
- Employees
- 6
- Address
- 400 N Aberdeen St,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- Chicago, Illinois
Tract Therapeutics, Inc. Questions
Tract Therapeutics, Inc.'s website is https://www.tracttherapeutics.com/
Tract Therapeutics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/tract-therapeutics
Tract Therapeutics, Inc. has
6 employees.
View email and phone details for 6
employees at Tract Therapeutics, Inc..
Tract Therapeutics, Inc.'s industry is
Biotechnology Research
Tract Therapeutics, Inc.'s top competitors are
Flashpoint Therapeutics,
Grove Biopharma, Inc.,
Siwa Therapeutics,
Circ Biosciences,
Emalex Biosciences,
Evozyne,
Paragon Biosciences,
Exicure,
Taiwan Bio Therapeutics Inc.,
Vanqua Bio.
Tract Therapeutics, Inc.'s categories are Biotechnology Research
